Maravai LifeSciences Announces November 2025 Investor Conference Schedule

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the month of November. On November 12, 2025, at 10:00 a.m. EST, Raj Asarpota, Chief Financial Officer, will participate in a fireside chat at the Stifel Healthcare Conference in New York City, NY. On November 19, 2025, at 10:00 a.m. GMT, Raj Asarpota, Chief Fin.

Business Wire • Nov 10, 2025

Maravai LifeSciences Holdings, Inc. (MRVI) Q3 2025 Earnings Call Transcript

Maravai LifeSciences Holdings, Inc. ( MRVI ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Debra Hart - Senior Director of Investor Relations Bernd Brust - CEO & Director Rajesh Asarpota - EVP & Chief Financial Officer Chanfeng Zhao - Senior VP & Chief Scientific Officer Conference Call Participants Justin Bowers - Deutsche Bank AG, Research Division Madeline Mollman - Wolfe Research, LLC Thomas Peterson - Robert W. Baird & Co. Incorporated, Research Division Nathan Bolanos - UBS Investment Bank, Research Division Matthew Stanton - Jefferies LLC, Research Division Presentation Operator Good afternoon, everyone.

Seeking Alpha • Nov 7, 2025

Maravai LifeSciences Reports Third Quarter 2025 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the third quarter ended September 30, 2025, together with other business updates. Quarterly Results: Revenue of $41.6 million, Net loss of $(45.1) million, and Adjusted EBITDA of $(10.8) million “We exited the third quarter confident about the future of our business. Cygnus co.

Business Wire • Nov 6, 2025

Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q3 Loss, Misses Revenue Estimates

Maravai LifeSciences Holdings, Inc. (MRVI) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.02 per share a year ago.

Zacks Investment Research • Nov 7, 2025

MARAVAI INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Maravai Long-Term Stockholders

Allegedly, Maravai misstated revenue and overstated goodwill due to weak internal controls, causing a 22% stock drop after delaying its earnings report.

GlobeNewsWire • Oct 29, 2025

Maravai LifeSciences To Host Earnings Conference Call on Thursday, November 6, 2025

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2025 financial and operating results after the market close on Thursday, November 6, 2025, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial (800) 579-2543 or (785) 424-1789 and reference M.

Business Wire • Oct 22, 2025

MARAVAI (MRVI) INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Investigation into Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Maravai (MRVI) To Contact Him Directly To Discuss Their Options If you purchased or acquired common stock in Maravai LifeSciences between August 7, 2024 and February 24, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner  Brandon Walker or Marion Passmore directly at (212) 355-4648 NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- What's Happening: Bragar Eagel & Squire, P.C.

GlobeNewsWire • Oct 2, 2025

MARAVAI INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Maravai (MRVI) To Contact Him Directly To Discuss Their Options If you purchased or acquired common stock in Maravai LifeSciences between August 7, 2024 and February 24, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner  Brandon Walker or Marion Passmore directly at (212) 355-4648 NEW YORK, Sept.

GlobeNewsWire • Sep 9, 2025

Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2025 Earnings Call Transcript

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q2 2025 Earnings Conference Call August 11, 2025 5:00 PM ET Company Participants Bernd Brust - CEO & Director Debra Hart - Senior Director of Investor Relations Rajesh J. Asarpota - EVP & Chief Financial Officer Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Catherine Walden Ramsey Schulte - Robert W.

Seeking Alpha • Aug 12, 2025

Maravai LifeSciences Reports Second Quarter 2025 Financial Results

Announced organizational restructuring and operating cost reduction initiatives targeting more than $50 million in annualized cost savings

GlobeNewsWire • Aug 11, 2025